Work

Nanoneoadjuvant Therapy of Gastrointestinal Stromal Tumor (GIST)

Year: 2009

Type: editorial

Abstract: Although it is clear that imatinib mesylate is highly effective in metastatic gastrointestinal stromal tumor (GIST), its optimal perioperative use is undefined.McAuliffe and colleagues now report a provocative study of a brief preoperative imatinib therapy. 1 Seventeen patients were randomized to receive 3, 5, or 7 days of 600 mg imatinib, underwent surgery immediately thereafter, and then received 2 years of adjuvant imatinib therapy.Radiologic, histologic, and surgical outcome measures were analyzed.

Source: Annals of Surgical Oncology

DOI: 10.1245/s10434-009-0316-9

Author: Ronald P. DeMatteo

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,590